Icosavax, Inc. (ICVX) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Icosavax, Inc.

ICVX

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

769M

Biotechnology

15.31USD

-0.14 ( -0.91%)

Market Closed (as of Feb 16, 21:00 EDT)

Relative Strenght

Volume Buzz

712%

Earning Acce

Yes

Dist 52w H.

Overview Chart

Quote Panel

Updated July 18, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
769.04M
Shares Outstanding
50.23M
Share in Float
29.30M
Dividende
0

Earning Date
No Data
Price Target
15.31
Average Volume
1.05M
Beta
1.278

Range
4.75-16.105
Industry
Biotechnology
Website
https://icosavax.com
Sector
Healthcare

Quote Panel

Updated July 18, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

N/A

P/E Ratio

1321.37x

P/S Ratio

2.79x

P/B Ratio

0.0

Debt/Equity

-15199.0%

Net Margin

$-2.2

EPS

How ICVX compares to sector?

P/E Ratio

Fundamentals

Relative Strength

ICVX

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

ICVX

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$2M

NaN%

2024-Revenue

$1.94

-342%

2024-EPS

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

0.00(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

Oppenheimer

initialise

Previous: Not converted

2023-01-04

Now: Outperform

Evercore ISI

upgrade

Previous: Not converted

2022-06-29

Now: Outperform

Earnings Growth

YoY

Current

Estimates

Q4.21

N/A

-0.46
vs -1.60

Q1.22

N/A

-0.60
vs -1.96

Q2.22

N/A

-0.57
vs -2.86

Q3.22

N/A

-0.55
vs -1.30

Q4.22

N/A

-0.59
vs -0.46

Q1.23

N/A

-0.60
vs -0.60

Q2.23

N/A

-0.59
vs -0.57

Q3.23

N/A

-0.44
vs -0.55

Q4.23

N/A

-0.58
vs -0.59

Q1.24

+363%

1.58
vs -0.60

Sales Growth

YoY

Current

Estimates

Q3.21

1.8M vs NA

Q4.21

-5732000.00 vs NA

Q1.22

-100%

NA vs 2M

Q2.22

-100%

NA vs 1.9M

Q3.22

-100%

NA vs 1.8M

Q4.22

+100%

NA vs -5732000

Q1.23

NA vs NA

Q2.23

NA vs NA

Q3.23

NA vs NA

Q4.23

420K vs NA

Return on Equity

QoQ

Q4.21

-7%

-0.07
vs -0.12

Q1.22

-9%

-0.09
vs -0.07

Q2.22

-9%

-0.09
vs -0.09

Q3.22

-9%

-0.09
vs -0.09

Q4.22

-10%

-0.10
vs -0.09

Q1.23

-11%

-0.11
vs -0.10

Q2.23

-11%

-0.11
vs -0.11

Q3.23

-9%

-0.09
vs -0.11

Institutionnal Ownership

QoQ

Q1.22

67
vs 53

26%

Q2.22

58
vs 67

-13%

Q3.22

68
vs 58

17%

Q4.22

70
vs 68

Q1.23

68
vs 70

-3%

Q2.23

66
vs 68

-3%

Q3.23

67
vs 66

Q4.23

100

100
vs 67

49%

Earnings Growth

Latest News

zacks.com

13 hours ago

Icosavax, Inc. (ICVX) Is Up 0.10% in One Week: What You Should Know

zacks.com

13 hours ago

Icosavax, Inc. (ICVX) Moves to Buy: Rationale Behind the Upgrade

businesswire.com

14 hours ago

ICVX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Icosavax, Inc. Is Fair to Shareholders

businesswire.com

16 hours ago

ICOSAVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX

prnewswire.com

17 hours ago

ICOSAVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX

businesswire.com

22 hours ago

ICOSAVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX

Company Description

15.31USD

N/A

1321.37x

2.79x

0.0

-15199.0%

$-2.2

$2M

$1.94

Earnings Growth

Latest News

Company Description

15.31USD

N/A

1321.37x

2.79x

0.0

-15199.0%

$-2.2